INZY Key Statistics, Chart & Performance
The current stock price of INZY is 4 USD. In the past month the price increased by 0.76%. In the past year, price decreased by -10.91%.
INZY Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.72 | 396.12B | ||
| AMGN | AMGEN INC | 15.09 | 177.76B | ||
| GILD | GILEAD SCIENCES INC | 14.73 | 149.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.06 | 119.17B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.8 | 84.19B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 783.14 | 52.76B | ||
| INSM | INSMED INC | N/A | 36.31B | ||
| NTRA | NATERA INC | N/A | 33.06B | ||
| BIIB | BIOGEN INC | 11.11 | 27.29B | ||
| INCY | INCYTE CORP | 16.5 | 20.79B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.6 | 21.14B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 20.76B |
Related stock screener links
About INZY
Company Profile
Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The company is headquartered in Boston, Massachusetts and currently employs 67 full-time employees. The company went IPO on 2020-07-24. The firm is engaged in developing therapeutics that target the pyrophosphate (PPi)-Adenosine Pathway, a key regulator of bone health and blood vessel function. Its lead product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, ENPP1 fusion protein that is designed to increase PPi and adenosine, to enable the potential treatment of multiple diseases caused by deficiencies in these molecules. The firm is conducting clinical trials of INZ-701 for the treatment of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency, ATP-Binding Cassette in the C6 family (ABCC6) Deficiency, and calciphylaxis. The firm also plans to investigate the potential of a next generation INZ-701 molecule to address posterior longitudinal ligament (OPLL).
Company Info
INOZYME PHARMA INC
321 Summer Street, Suite 400
Boston MASSACHUSETTS 02210 US
CEO: Axel Bolte
Employees: 67
Phone: 18573304340
INOZYME PHARMA INC / INZY FAQ
What does INOZYME PHARMA INC do?
Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The company is headquartered in Boston, Massachusetts and currently employs 67 full-time employees. The company went IPO on 2020-07-24. The firm is engaged in developing therapeutics that target the pyrophosphate (PPi)-Adenosine Pathway, a key regulator of bone health and blood vessel function. Its lead product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, ENPP1 fusion protein that is designed to increase PPi and adenosine, to enable the potential treatment of multiple diseases caused by deficiencies in these molecules. The firm is conducting clinical trials of INZ-701 for the treatment of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency, ATP-Binding Cassette in the C6 family (ABCC6) Deficiency, and calciphylaxis. The firm also plans to investigate the potential of a next generation INZ-701 molecule to address posterior longitudinal ligament (OPLL).
Can you provide the latest stock price for INOZYME PHARMA INC?
The current stock price of INZY is 4 USD. The price increased by 0.25% in the last trading session.
Does INOZYME PHARMA INC pay dividends?
INZY does not pay a dividend.
How is the ChartMill rating for INOZYME PHARMA INC?
INZY has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What do analysts say about INOZYME PHARMA INC (INZY) stock?
13 analysts have analysed INZY and the average price target is 6.85 USD. This implies a price increase of 71.21% is expected in the next year compared to the current price of 4.
Can you provide the sector and industry classification for INOZYME PHARMA INC?
INOZYME PHARMA INC (INZY) operates in the Health Care sector and the Biotechnology industry.
What is the market capitalization of INZY stock?
INOZYME PHARMA INC (INZY) has a market capitalization of 258.24M USD. This makes INZY a Micro Cap stock.
INZY Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to INZY. When comparing the yearly performance of all stocks, INZY is one of the better performing stocks in the market, outperforming 98.56% of all stocks.
INZY Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to INZY. INZY has a bad profitability rating. Also its financial health evaluation is rather negative.
INZY Financial Highlights
Over the last trailing twelve months INZY reported a non-GAAP Earnings per Share(EPS) of -1.68. The EPS decreased by -24.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -112.14% | ||
| ROE | -335.61% | ||
| Debt/Equity | 0.65 |
INZY Forecast & Estimates
13 analysts have analysed INZY and the average price target is 6.85 USD. This implies a price increase of 71.21% is expected in the next year compared to the current price of 4.